SIGA Technologies, Inc., is a pharmaceutical company. The Company is focused on specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats. The Company’s lead product is Arestvyr (tecovirimat) also known as ST-246, an orally administered antiviral drug that targets orthopoxviruses. While Arestvyr is not yet licensed as safe or effective by the U.S. Food & Drug Administration, it is a small-molecule drug that is being delivered to the strategic national stockpile under Project BioShield. Arestvyr is an investigational product that is not currently approved by the U.S. Food and Drug Administration (FDA) as a treatment of smallpox or any other indication.